[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339360-105":3,"doc-detail-339360-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deciphering-the-functional-role-of-clinical-mutations-in-abcb1-abcc1-and-abcg2-abc-transporters-in-endometrial-cancer","Deciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in endometrial cancer","","ATP-binding cassette (ABC) transporters are dynamic membrane proteins that drive therapy resistance by exporting substrates across cellular membranes. This study analyzes clinical mutations reported in endometrial cancers for ABCB1, ABCC1, and ABCG2 to clarify how substrate binding and drug efflux functions are altered. Most ABCB1 and ABCG2 key mutations cluster in membrane-facing regions, whereas ABCC1 mutations predominantly occur in the inactive nucleotide-binding domain. Identified and cross-cancer common mutations may support inhibitor design and transporter re-engineering to overcome chemoresistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deciphering-the-functional-role-of-clinical-mutations-in-abcb1-abcc1-and-abcg2-abc-transporters-in-endometrial-cancer/339360/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deciphering-the-functional-role-of-clinical-mutations-in-abcb1-abcc1-and-abcg2-abc-transporters-in-endometrial-cancer/339360.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in endometrial cancer treatment?","Question",{"text":63,"@type":64},"The study focuses on therapy resistance, particularly how drug efflux mediated by ABC transporters contributes to reduced chemotherapy effectiveness.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the mutation locations differ among ABCB1, ABCC1, and ABCG2?",{"text":68,"@type":64},"For ABCB1 and ABCG2, most key mutations are concentrated in membrane-facing regions, while for ABCC1 most key mutations are in the inactive nucleotide-binding domain.",{"name":70,"@type":61,"acceptedAnswer":71},"How can the identified mutations be used clinically or in drug development?",{"text":72,"@type":64},"The mapped key mutations and common cross-cancer variants can help design and discover inhibitors targeting less-explored transporter regions and support re-engineering strategies to counter chemoresistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339360,1790177079,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267",8,"TYPE Original Research PUBLISHED 02 May 2024  \nDOI 10.3389/fphar.2024.1380371  \nOPEN ACCESS  \nEDITED BY  \nMuhammad Rafehi,  \nUniversity Medical Center Göttingen, Germany  \nREVIEWED BY  \nZufeng Guo,  \nChongqing Medical University, China Katja Stefan,  \nUniversity of Lübeck, Germany  \n*CORRESPONDENCE  \nManu Smriti Singh,  \n [manu.singh@mahindrauniversity.edu.in](manu.singh@mahindrauniversity.edu.in)[ ](manu.singh@mahindrauniversity.edu.in)Bipin Singh,  \n [bipin.singh@mahindrauniversity.edu.in](bipin.singh@mahindrauniversity.edu.in)  \nRECEIVED 01 February 2024  \nACCEPTED 28 March 2024  \nPUBLISHED 02 May 2024  \nCITATION  \nGupta A, Singh MS and Singh B (2024), Deciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in endometrial cancer.  \nFront. Pharmacol. 15:1380371 .  \ndoi: 10.3389/fphar.2024.1380371  \nCOPYRIGHT  \n© 2024 Gupta, Singh and Singh. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDeciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in  \nendometrial cancer  \nAayushi Gupta 1, Manu Smriti Singh 1,2* and Bipin Singh 1*  \n1Centre for Life Sciences, Mahindra University, Hyderabad, India, 2Interdisciplinary Centre for Nanosensors and Nanomedicine, Mahindra University, Hyderabad, India  \nATP-binding cassette transporters represent a superfamily of dynamic membrane-based proteins with diverse yet common functions such as use of ATP hydrolysis to efﬂux substrates across cellular membranes. Three major transporters—P-glycoprotein (P-gp or ABCB1), multidrug resistance protein 1 (MRP1 or ABCC1), and breast cancer resistance protein (BCRP or ABCG2) are notoriously involved in therapy resistance in cancer patients. Despite exhaustive individual characterizations of each of these transporters, there is a lack of understanding in terms of the functional role of mutations in substrate binding and efﬂux, leading to drug resistance. We analyzed clinical variations reported in endometrial cancers for these transporters. For ABCB1, the majority of key mutations were present in the membrane-facing region, followed by the drug transport channel and ATP-binding regions. Similarly, for ABCG2, the majority of key mutations were located in the membrane-facing region, followed by the ATP-binding region and drug transport channel, thus highlighting the importance of membrane-mediated drug recruitment and efﬂux in ABCB1 and ABCG2 . On the other hand, for ABCC1, the majority of key mutations were present in the inactive nucleotide-binding domain, followed by the drug transport channel and membrane-facing regions, highlighting the importance of the inactive nucleotide-binding domain in facilitating indirect drug efﬂux in ABCC1 . The identiﬁed key mutations in endometrial cancer and mapped common mutations present across different types of cancers in ABCB1, ABCC1, and ABCG2 will facilitate the design and discovery of inhibitors targeting unexplored structural regions of these transporters and re-engineering of these transporters to tackle chemoresistance.  \nKEYWORDS  \ncancer, ATP-binding cassette transporters, chemoresistance, mutation, mitoxantrone, drug resistance, efﬂux transporters  \n1 Introduction  \nDespite tremendous advancements in the treatment of clinical cancer via chemotherapy, radiotherapy, immunotherapy, etc., the development of therapy resistance remains a major challenge and concern for clinicians and researchers alike. The most common mechanisms of resistance include drug efﬂux, DNA repair, alteration of drug targets, inactivation or sequestration of dru","cbCaiuH3l1HBAGHf","https://ap.wps.com/l/cbCaiuH3l1HBAGHf","pdf",3204038,16,"English","# Introduction\n## Therapy resistance and drug efflux mechanisms\n## Role and structure of ABC transporters","[{\"question\":\"What problem does the study address in endometrial cancer treatment?\",\"answer\":\"The study focuses on therapy resistance, particularly how drug efflux mediated by ABC transporters contributes to reduced chemotherapy effectiveness.\"},{\"question\":\"How do the mutation locations differ among ABCB1, ABCC1, and ABCG2?\",\"answer\":\"For ABCB1 and ABCG2, most key mutations are concentrated in membrane-facing regions, while for ABCC1 most key mutations are in the inactive nucleotide-binding domain.\"},{\"question\":\"How can the identified mutations be used clinically or in drug development?\",\"answer\":\"The mapped key mutations and common cross-cancer variants can help design and discover inhibitors targeting less-explored transporter regions and support re-engineering strategies to counter chemoresistance.\"}]","Deciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in endometrial cancer | PDF",1790029810,40,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf095b45db1fa14b5a3cbec53899fd66.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e27f3e3fabeac27cb52b6c34465a0aa.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17068e2ad87bcb1714955b381b388ee1.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3abb340d03ef7648e63cabb2e851c2d.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,139,143,146,151,154,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":98,"slug":142},7,"Healthcare","healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":144,"slug":145},30,"research-report",{"id":147,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":149,"slug":150},9,"Religion & Spirituality",20,"religion-spirituality",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":149,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":131,"slug":161},19,"General","general"]